Efficacy of weight-based reslizumab dosing is consistent across body weights in post-hoc analysis

Rationale: Intravenous (IV) reslizumab (RES), a humanized anti-interleukin-5 monoclonal antibody, significantly reduces risk of clinical asthma exacerbations (CAEs) and improves lung function, asthma control, and quality of life in adult patients with uncontrolled eosinophilic asthma. IV RES dosing is weight based; we evaluated therapeutic effect across body weights. Methods: In a post-hoc analysis of two randomized, 52-week, PBO-controlled phase 3 trials of RES (3 mg/kg IV Q4W) in patients on at least medium dose ICS at baseline, patients were analyzed by weight category ( 1 , ACQ, and AQLQ at 52 weeks were reported in the overall population and the GINA 4/5 subgroup. Results: The trials included 953 patients (RES 477; PBO 476) with 383 and 380 in the GINA 4/5 subgroup. For the overall population, the LOW weight group ranged from 33.9 to 1 , ACQ and AQLQ scores at 52 weeks with RES vs PBO (Table). Conclusions: Weight-based dosing of IV RES was associated with consistent improvements in CAE rates, lung function, and patient-reported outcomes in inadequately controlled eosinophilic asthma patients, including patients with severe asthma, irrespective of body weight.